Simon obtained his degree and PhD in organic chemistry from the University of East Anglia, and completed two post-doctoral positions in Lisbon and Birmingham before moving into industry in 2006. After a brief spell working at Pfizer Simon joined SAFC Pharma in early 2007 as a shift chemist on the GMP production plant.
Simon’s ability to effectively trouble shoot and identify process improvements gave him the opportunity to progress within SAFC, holding several positions of increasing responsibility before being appointed plant manager.
In 2013 Simon made the switch to gene therapy, moving to Oxford Biomedica. As the Vice President, Head of Manufacturing Simon has overseen the expansion the Manufacturing department, increasing production output by eliminating process wastage and through two capacity expansion projects. Five years after bring manufacturing in-house, Oxford Biomedica was approved as the world’s first commercial manufacture of a Lentiviral vector gene therapy and continues to make strides in reducing the cost of ATMP’s by the introduction of its second generation suspension process.